With the beginning of the high-throughput screening, in silico-based drug response analysis has opened lots of research avenues in the field of personalized medicine. For a decade, many different predicting techniques have been recommended for the antineoplastic (anti-cancer) drug response, but still, there is a need for improvements in drug sensitivity prediction. The intent of this research study is to propose a framework, namely NeuPD, to validate the potential anti-cancer drugs against a panel of cancer cell lines in publicly available datasets. The datasets used in this work are Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). As not all drugs are effective on cancer cell lines, we have worked on 10 essential drugs from the GDSC dataset that have achieved the best modeling results in previous studies. We also extracted 1610 essential oncogene expressions from 983 cell lines from the same dataset. Whereas, from the CCLE dataset, 16,383 gene expressions from 1037 cell lines and 24 drugs have been used in our experiments. For dimensionality reduction, Pearson correlation is applied to best fit the model. We integrate the genomic features of cell lines and drugs’ fingerprints to fit the neural network model. For evaluation of the proposed NeuPD framework, we have used repeated K-fold cross-validation with 5 times repeats where K = 10 to demonstrate the performance in terms of root mean square error (RMSE) and coefficient determination (R²). The results obtained on the GDSC dataset that were measured using these cost functions show that our proposed NeuPD framework has outperformed existing approaches with an RMSE of 0.490 and R² of 0.929.

Personalized medicine in cancer treatment aims to treat each individual’s cancer tumor uniquely based on the genetic sequence of the cancer patient and is a much more effective approach compared to traditional methods which involve treating each type of cancer in the same, generic manner. However, personalized treatment requires the classification of cancer-related genes once profiled, which is a highly labor-intensive and time-consuming task for pathologists making the adoption of personalized medicine a slow progress worldwide. In this paper, we propose an intelligent multi-class classifier system that uses a combination of Natural Language Processing (NLP) techniques and Machine Learning algorithms to automatically classify clinically actionable genetic mutations using evidence from text-based medical literature. The training data set for the classifier was obtained from the Memorial Sloan Kettering Cancer Center and the Random Forest algorithm was applied with TF-IDF for feature extraction and truncated SVD for dimensionality reduction. The results show that the proposed model outperforms the previous research in terms of accuracy and precision scores, giving an accuracy score of approximately 82%. The system has the potential to revolutionize cancer treatment and lead to significant improvements in cancer therapy.

Background/Objectives: Cancer is a chronic and heterogeneous disease, possessing molecular variation within a single type, resulting in its molecular subtypes. Cancer molecular subtyping offers biological insights into cancer variability, facilitating the development of personalized medicines. Various models have been proposed for cancer molecular subtyping, utilizing the high-dimensional transcriptomic, genomic, or proteomic data. The issue of data scarcity, characterized by high feature dimensionality and a limited sample size, remains a persistent problem.The objective of this research is to propose a deep learning framework, DeepCMS, that leverages the capabilities of feed-forward neural networks, gene set enrichment analysis, and feature selection to construct a well-representative subset of the feature space, thereby producing promising results. Methods: The gene expression data were transformed into enrichment scores, resulting in over 22,000 features. From those, the top 2000 features were selected, and deep learning was applied to these features. The encouraging outcomes indicate the efficacy of the proposed framework in terms of defining a well-representative feature space and accurately classifying cancer molecular subtypes. Results: DeepCMS consistently outperformed state-of-the-art models in aggregated accuracy, sensitivity, specificity, and balanced accuracy. The aggregated metrics surpassed 0.90 for all efficiency measures on independent test datasets, showing the generalizability and robustness of our framework. Although developed using colon cancer’s gene expression data, this approach may be applied to any gene expression data; a case study is also devised for illustration. Conclusions: Overall, the proposed DeepCMS framework enables the accurate and robust classification of cancer molecular subtypes using a compact and informative feature set, facilitating improved precision in oncology applications.